Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
45 Results for "
DXd
" in MedChemExpress (MCE) Product Catalog:
Products (45)
45 Results for "DXd" in MCE Product Catalog:
Cat. No.: HY-164919
CAS No.: 2847102-44-5
Synonyms: XMT-2056
Research Areas:
Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate (ADC) targeting HER2, linked to a payload composed of XMT-1519 conjugate-1 (HY-148067) and STING agonist-20 (HY-148068). Calotatug ginistinag activates the STING signaling pathway in tumor cells and tumor-resident immune cells, induces the production of type I interferons and cytokines (CXCL10, IFN-β, IL-6, TNF-α, triggers innate anti-tumor immune responses, and exerts a bystander effect. Calotatug ginistinag exhibits efficacy against HER2-expressing cancer cells in co-culture with PBMCs. Calotatug ginistinag induces tumor regression and reduces systemic inflammation in various tumor models. Combination treatment with Calotatug ginistinag, Trastuzumab (HY-P9907) and T-DXd (HY-138298) yields benefits. Calotatug ginistinag can be used in studies related to HER2-expressing solid tumors such as breast cancer, gastric cancer and ovarian cancer .
Cat. No.: HY-176415
CAS No.: 3025787-83-8
Target:
Research Areas:
Cys-MC-GGFG-Dxd is a cysteine-modified, cleavable ADC drug-linker conjugate. Cys-MC-GGFG-Dxd consists of a maleimidocaproyl-glycine-glycine-L-phenylalanine-glycine (MC-GGFG) linker and an Exatecan (HY-13631) derivative (DXd) (HY-13631D) payload. Cys-MC-GGFG-Dxd can be further conjugated to anti-HER2 IgG1κ antibody for the synthesis of antibody-drug conjugates (ADC), such as the breast cancer-targeting ADC compound Fam-trastuzumab deruxtecan-nxki (Enhertu) .
Cat. No.: HY-158137
CAS No.: 2964543-53-9
Target:
Research Areas:
Val-Cit-PAB-DEA-Dxd (compound 81) is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule Dxd (DNA topoisomerase I inhibitor). Val-Cit-PAB-DEA-Dxd can be used for ADC synthesis .
Cat. No.: HY-160098
CAS No.: 2566530-81-0
Target:
Research Areas:
BCN-linker-DXd 2 is a specialized antibody-drug conjugate (ADC) payload-linker complex carrying a derivative of the cytotoxic agent DXd (HY-13631D). BCN-linker-DXd 2 bears a BCN (bicyclononyne) group for click chemical bioconjugation, and can be used for ADC synthesis .
Cat. No.: HY-13631ES3
CAS No.: 2760715-87-3
Synonyms: MC-GGFG-DXd-d2
Cat. No.: HY-13631ES
CAS No.: 2760715-91-9
Synonyms: MC-GGFG-DXd-d4
Cat. No.: HY-178262A
CAS No.: 2806052-35-5
Target:
Research Areas:
thioxo-Dxd is a Camptothecin (HY-16560) derivative. thioxo-Dxd can be connected to monoclonal antibodies via linkers to form antibody-drug conjugate (ADC) molecules. thioxo-Dxd can be used for research on tumors with high HER2 or TROP2 expression .
Cat. No.: HY-158137A
Target:
Research Areas:
Val-Cit-PAB-DEA-Dxd (Compound 81) TFA is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule Dxd (HY-13631D). Val-Cit-PAB-DEA-Dxd can be used for ADC synthesis .
Cat. No.: HY-13631ES2
CAS No.: 2760715-88-4
Synonyms: MC-GGFG-DXd-d4-1
Cat. No.: HY-13631ES1
CAS No.: 2760715-89-5
Synonyms: MC-GGFG-DXd-d6
Cat. No.: HY-178262
CAS No.: 2806052-36-6
Target:
Research Areas:
(R)-thioxo-Dxd is a Camptothecin (HY-16560) derivative. (R)-thioxo-Dxd can be connected to monoclonal antibodies via linkers to form antibody-drug conjugate (ADC) molecules. (R)-thioxo-Dxd can be used for research on tumors with high HER2 or TROP2 expression .
Cat. No.: HY-176415S
Cat. No.: HY-13631K
CAS No.: 2766786-58-5
Target:
Research Areas:
(1R,9S)-Dxd is an isomer of (Dxd) HY-13631D. (1R,9S)-Dxd is an ADC payload that can be used in the synthesis of ADCs (antibody-drug conjugates) .
Cat. No.: HY-168285
CAS No.: 2718125-83-6
Research Areas:
LE01 is a drug-linker conjugate for ADC. LE01 contains a ADC linker and a DNA topoisomerase I inhibitor DXd (HY-13631D). LE01 can be used to synthesize HER2-targeting ADC (HER2-LE01) .
Target:
Research Areas:
Deruxtecan analog 2 (monoTFA) is a homolog of Deruxtecan (HY-13631E), a conjugate of the ADC toxin DX-8951 derivative (Dxd) with an ADC Linker .
Cat. No.: HY-177414
Research Areas:
BB-1701 is an anti-HER2 antibody-drug conjugate (ADC). BB-1701 consists of a humanized anti-HER2 antibody (Trastuzumab) (HY-P9907), a linker (Mal-PEG2-VCP), and a microtubule inhibitor (Eribulin) (HY-13442), with the drug-linker conjugate of the ADC being Mal-PEG2-VCP-Eribulin (HY-128870). BB-1701 exhibits potent cytotoxicity against various cancer cells, shows a remarkable bystander effect, and induces immunogenic cell death (upregulated cell surface expression of calreticulin, release of ATP/HMGB1, macrophage infiltration) and apoptosis. BB-1701 potently inhibits tumor growth in T-DM1/T-DXd-resistant tumor models. BB-1701 can be used in studies related to breast cancer, gastric cancer, non-small cell lung cancer, and heterogeneous mixed tumors .
Cat. No.: HY-176415S1
Synonyms: Cys-MC-GGFG-DXd-d5 TFA
Cat. No.: HY-W1124025
CAS No.: 2813268-45-8
Target:
Research Areas:
(5-Cl)-DXd, a derivative of DXd (HY-13631), is a cytotoxic drug that can be used in synthesis of CDH3-targeting antibody-drug conjugates (ADCs) .
Cat. No.: HY-13631DS1
CAS No.: 2760715-90-8
Synonyms: Exatecan derivative for ADC-d2
Cat. No.: HY-138298B
CAS No.: 1826843-81-5
Synonyms: T-DXd (DAR2); DS-8201 (DAR2); DS-8201a (DAR2)
Target:
Research Areas:
Trastuzumab deruxtecan (DAR2) (T-DXd (DAR2); DS-8201 (DAR2); DS-8201a (DAR2)) is a low-drug-load derivative control preparation of Trastuzumab deruxtecan (HY-138298A) with a drug-to-antibody ratio (DAR) of 2. Trastuzumab deruxtecan (T-DXd; DS-8201a; DS-8201) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
